Acadia Healthcare Company, Inc. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Acadia Healthcare Company, Inc. is a leading provider of behavioral healthcare services, operating 274 facilities with approximately 12,100 beds across 39 states and Puerto Rico. The company operates through acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers (CTCs), and residential treatment centers.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $869.2 million | $796.0 million | $1,639.7 million | $1,564.1 million |
| Net Income (Attributable to Acadia) | $30.1 million | $78.5 million | $38.5 million | $154.9 million |
| Diluted EPS | $0.33 | $0.85 | $0.42 | $1.68 |
| Operating Cash Flow (YTD) | $145.0 million (2025) vs. $(150.1) million (2024) | |||
| Cash and Equivalents | $131.4 million (as of June 30, 2025) | |||
| Total Debt (Long-term + Current) | $2.27 billion (as of June 30, 2025) | |||
| Net Leverage Ratio | 3.2x (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 9.2% year-over-year for Q2 2025 and 4.8% for the six-month period. This growth was driven by a 7.5% increase in revenue per patient day and a 1.8% increase in patient days on a same-facility basis. A significant portion of Q2 revenue ($65.6 million) was recognized due to the timing of a state government program approval.
- Profitability Decline: Net income attributable to the company dropped significantly, down 61.6% in Q2 and 75.1% YTD compared to 2024. This decline is primarily attributed to a substantial increase in "Transaction, legal and other costs."
- Expense Increases:
- Transaction/Legal Costs: Rose to $64.4 million in Q2 2025 from $6.1 million in Q2 2024. This includes $53.5 million related to government investigations.
- Salaries and Wages: Increased to $452.4 million in Q2 2025 (52.0% of revenue) from $419.8 million in Q2 2024, reflecting wage inflation and equity-based compensation.
- Interest Expense: Increased to $35.1 million in Q2 2025 due to the issuance of new Senior Notes in Q1 2025.
- Capital Expenditures: YTD 2025 capital expenditures were $342.4 million, with $291.2 million classified as expansion capex.
Guidance, Outlook, and Risks
- Debt Refinancing: In February 2025, the company entered a new $1.65 billion credit facility ($1.0 billion revolving, $650 million term loan) maturing in 2030. In March 2025, it issued $550 million of 7.375% Senior Notes due 2033. Proceeds were used to refinance prior debt and pay down the revolving facility.
- Share Repurchases: The board authorized a $300 million share repurchase program in February 2025. As of June 30, 2025, $50.4 million had been utilized, with $250 million remaining.
- Legal and Regulatory Risks:
- Government Investigations: The company is subject to ongoing investigations by the DOJ Criminal Division and SEC regarding admissions, length of stay, and billing practices. Legal fees and settlement costs related to these investigations were a major driver of Q2 expenses.
- Desert Hills Litigation: While a $400 million settlement was paid in January 2024 to resolve five cases, a sixth lawsuit was filed in January 2024. The company cannot currently estimate the liability for this new case.
- Securities Litigation: Multiple putative class action lawsuits and derivative actions are pending, alleging violations of securities laws and fiduciary duties.
- Legislative Impact: The "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 introduces Medicaid changes, including work requirements and provider tax restrictions starting in 2026 and 2028. Management does not expect a material immediate impact due to exemptions for their patient population.
Investor Verification Checklist
- Legal Cost Sustainability: Verify the trajectory of "Transaction, legal and other costs," specifically the $53.5 million in government investigation fees, to assess if this is a one-time spike or a recurring burden.
- Revenue Quality: Confirm the sustainability of the $65.6 million revenue recognized in Q2 due to state program approval timing and its impact on future quarters.
- Debt Service Capacity: Review the impact of the new 7.375% Senior Notes and increased interest rates on future EBITDA and cash flow coverage ratios.
- Investigation Outcomes: Monitor updates on the DOJ and SEC investigations regarding billing practices and the pending sixth Desert Hills lawsuit for potential future liabilities.
- Same-Facility Metrics: Analyze the divergence between consolidated revenue growth (4.8% YTD) and same-facility revenue growth (5.8% YTD) to understand organic performance versus acquisition impact.